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THE value of cytotoxic agents in the treatment of cancer is now established,
and the comparative place ofthe many available agents in different tumours is now
becoming clear (Davies 1964). In this respect, methotrexate is accepted as
the drug of choice for epithelioma of the head and neck, although it is less clear
how and when it should be employed.
Given intra-arterially and used as the sole agent in regional infusion therapy,
about 10% of tumours are cured and nearly 50 % show partial regression (Burn,
1964; Johnston, 1964). Although these results are full of promise they are
nonetheless disappointing. Some form of adjuvant therapy has therefore been
recommended. Philip (1964) has shown that the cure rate can be improved when
methotrexate is combined with radiotherapy, and Routledge (1964) has used it
before surgical excision of a tumour. Although improved survival figures can be
shown by combined techniques, they are small in relation to the numbers who
show local recurrence of their tumours. A new method of treatment, in which
methotrexate was infused intra-arterially before and after surgical excision of the
tumour, seemed worthy of trial. Before starting such a trial we wished to study
the effect of methotrexate on wound healing experimentally.
MATERIALS
We chose white Norwegian (" Wistar ") rats because they had been used in the
study of wound healing many times before, and the findings appear to be com-
parable with those in man. All were young (4-6 weeks) females.
METHODS
Four standard wounds were made on the backs of a group of rats of similar
weight and the animals allocated at random to one form of treatment. Adequate
controls were used in every experiment. The tensile strength of the wounds was
measured 3, 5 and 7 days after wounding, using a Sandblom tensiometer (Calnan
and Fry, 1963). The measurements were made without reference to treatment,
and the data examined by an analysis of variance. The methotrexate, or other
drug, was freshly made up and given intraperitoneally in 1 c.c. volumes each day.
The rats were housed in separate cages at room temperature and fed on a pellet
diet (Dixon's No. 7) with water ad libitum.
Six experiments were performed.
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EXPERIMENTS AND RESULTS
I. Effect of various cytotoxic agents on wound healing
Number of rats 24, mean weight 154 g. (S.D. 8 5)
Experimental design = incomplete random block.
Treatments: 1. Methotrexate: 0-375 mg./kg./day
2. 5-Fluorouracil: 7-5 mg./kg./day
3. Cyclophosphamide: 7-5 mg./kg./day
4. Control: Saline only.
The tensile strength of the standard wounds, measured at 5 days, are shown
in Fig. 1. It is clear from this that methotrexate depresses wound healing to a
CONTROL . . .
5-FLUOROURACIL
PHOSPHAMIDE
METHOTREXATE e
0 50 100 150
TENSILE STRENGTH (g. Force)
FIG. 1.-Chart of mean tensile strength of wounds in rats at 5 days. The effect of
methotrexato is significant (P < 0 05) (experiment I).
significant degree (P < 0 5), and cyclophosphamide not at all. When one
considers the loss of weight of the rats during the experiment, a reverse order is
found (Table I). Some loss of weight (due to wounding, daily injections, and a
TABLE I.-Weight Changes of Wounded Rats
Mean weights of rats at Alean loss ofweight after
Treatment start of experiment 5 days treatment
(g.) (g.)
5-Fluorouracil . . 154-2 . 22-0
Cyclophosphamide . 155-3 29- 5
Methotrexate . 157-3 16- 8
Control . 150-6 . 13- 8
body dressing) is common, but the loss when cyclophosphamide is given is more
than twice that of the controls.
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11. The inter-actions between cytotoxic drugs
Number of rats - 56, mean weight 168 g. (S.D. 10.4)
Experimental design = Factorial
Treatments: 1. Methotrexate: 0 125 mg./kg./day
2. 5-Fluorouracil: 2-5 mg./kg./day
3. Cyclophosphamide: 2 5 mg./kg./day
4. Saline only
Tensile strength measured at 5 days after wounding.
The results in Table II demonstrate that, although the tensile strengths ofthe
treated wounds are less than those ofthe controls, there is little difference between
TABLE II.-Tensile Strength of 5-Day Wounds
(Factorial Experiment)
Tensile strength in grams
force (S.E. 18 - 7)
Methotrexate
Treatment ,__-__ (for dosage see text) Given Not given
5-Fluorouracil
plus cyclophosphamide . 107 6 135- 6
5-Fluorouracil . . . 110-0 126- 7
Cyclophosphamide . . 122- 0 148- 7
Methotrexate only . 105-6
No drug: controls . . 154 7
various treatments. Methotrexate appears to have a more depressing effect on
woundhealing thantheother drugsbut the difference is not statisticallysignificant.
In general the effect on wound healing agrees with the findings of experiment I
and does not indicate any interaction between the three cytotoxic agents tested.
III. Dose-response curve of methotrexate
Number of rats - 20, mean weight 161 g. (S.D. 9-9).
Experimental design _ incomplete random block
Treatments (4): Methotrexate 0a125 mg./kg./day
0 25 mg./kg./day
0 5 mg./kg./day
1 0 mg./kg./day
Tensile strength measured at 5 days.
The effect of increasing doses of methotrexate on wound tensile strength is
shown in Fig.2. Wound healing appears to be depressed significantly at a dose
*of 0 3 mg./kg., and markedly affected at 0 9 mg./kg.-corresponding to the oral
systemic and intra-arterial infusion doses used in man.
IV. Effect ofpre- and post-operative methotrexate on wound healing
Number of rats 24, mean weight 144 g. (S.D. 9 3).
Experimental design = incomplete random block.
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Treatments: Methotrexate 0X05 mg./kg./day for 5 days before wounding:
nil after.
Methotrexate 0 05 mg./kg./day for 5 days before and 5 days
after wounding.
Methotrexate 0 05 mg./kg./day for 5 days after wounding only.
Controls: no drug: saline only
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FIG. 2.-Dose-response curve with methotrexate on the tensile strength of 5-day-
old wounds in rats (experiment III).
The results in Fig. 3. show that the post-operative exhibition ofmethotrexate,
in this rather small dosage, has a more depressing effect on healing than whenused
before operation.
V. The protective effect offolinic acid
Number of rats = 20, mean weight 192 g. (S.D. 15).
Experimental design = incomplete random block.
Treatments: Methotrexate 0 5 mg./kg./day
Methotrexate 0 5 mg./kg./day
{Folinic acid (Leucovorin) 2X5 mg./kg./day
Folinic acid (Leucovorin) 2-5 mg./kg./day
Controls: Saline only.
The results are shown in Fig. 4. It is clear that methotrexate in this large
dosage depressed wound healing when the tensile strength was measured at 3 and
7 days, but that Leucovorin (folinic acid)will protect completely. It is interesting
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FIG. 3. The effect of pre- and post-operative methotrexate (0 05 mg./kg.) on the tensile
strength of 5-day-old wounds in rats. The post-operative use of methotrexate causes a
significant depression of tensile strength (P < 0 05).
to note that Leucovorin when given alone appeared to enhance wound healing in
the early stages to a significant degree (P < 01) but this effect is short-lived.
VI. The effect of Leucovorin (folinic acid) on wound healing
Number of rats = 16, mean weight 73 g. (S.D. 5).
Experimental design - incomplete random block.
Treatments: Leucovorin 7.5 mg./kg./day subcutaneously in 1 ml.
0.75 mg./kg./day
0 075 mg./kg./day
Controls: saline injections.
The wounds were measured at 5 days but no statistically significant differences
were noted. The mean tensile strength in each group, however, was related to the
dose of folinic acid-the larger the dose, the greater the tensile strength (Table
III).
TABLE III.-Effect of Folinic Acid (Leucovorin) on 5-Day Wounds
Folinic acid Mean tensile strength (g. force) & S.E.
15 mg./kg. . 250 + 12- 8
1-5 mg./kg. . 235
0-15 mg./kg. .190 ,.
Controls . . 227 ,.
The effect at 5 days is not statistically significant (compare with Fig. 4).
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FIG. 4. The protective effect of folinic acid (Leucovorin). At a dosage of 0 5 mg./kg. methotrexate causes a significant depression of wound healing (P < 0-01) but folinic acid
(2.5 mg./kg.) will prevent this.
DISCUSSION
Methotrexate (Amethopterin) is a potent folic acid antagonist and cytotoxic
agent, with the formula 4-amino-N'0-methyl-pteroyl-glutamic acid. Its action is
to prevent the reduction of folic acid to tetrahydrofolic acid by uniting with
dihydrofolic reductase, the substance which catalyses the process. The affinity of
methotrexate for the enzyme is about 100,000 times greater than that of the
normal substrate.
Folic acid is an essential starting substance for the formation of analogues
whose function is to introduce single carbon atoms into a number of molecules.
It is through this mechanism that folic acid is involvedinnucleic acid and purine
synthesis. Methotrexate blocks this process, and probably produces most of its
effects by interfering with purine synthesis.
When given intravenously methotrexate is excreted in the urine and cleared
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from the tissues within 24 hours. Its biological effect is probably due to its
damaging action on all rapidly dividing cells. It also damages tumour cells which
are apparently slightly more vulnerable to the drug than normal tissues.
The maximum dose for a 60 kg. adult, by mouth is about 10 mg./day (0-15
mg./kg), and by arterial infusion about 100 mg./day (1.5 mg./kg). It is a powerful
cytotoxic agent and should be used with caution. Folinic acid (Leucovorin)
is a potent antidote, but is only effective ifgiven within 4 hours of the administra-
tion of methotrexate. Jacobson (1964) has suggested that some cells have the
capacity to inactivate methotrexate by ring closure of the terminal glutamic-acid
part of the molecule, and though there was evidence that leukaemic cells might
synthesise folic acid from precursors. There is, however, a lack of precise know-
ledge of the clinical action of cytotoxic agents generally, which at present makes
their use rather empirical.
In these six controlled experiments we have studied the effect on wound
healing of varying doses of methotrexate. It is clear that this anti-metabolite
has a markedly detrimental effect on the early stages of sound repair (experiments
III, IV, V) which is proportional to the dose used (experiment III). This is what
one might expect from a knowledge of its biochemical action. We have also
shown no synergesim with one other anti-metabolite, 5-fluorouracil (experiment
II), and no summation of effect. We were, however, unable to demonstrate any
noticeable effect on healing by the alkylating agent, cyclophosphamide, in contrast
to the work of Desprez and Kiehn (1960).
Most of the publications on the effect of anti-cancer drugs on wound healing
have concerned the nitrogen mustards. There is general agreement that these are
detrimental to healing (Kaiser, Herter, Mahn, DeMetz, and Campione 1961;
Hardesty, 1958; Farhat, Weeks and Musselman 1958), although Conn, Leb and
Hardy (1957) were unable to show any ill effects from nitrogen mustard (0.4
mg./kg. i.v.) or thiotepa (2.0 mg./kg. i.m.) in dogs. Staley, Kukral and Preston
(1962) found a significantly adverse effect from 5-fluorouracil (p < 0.05) and
nitrogen mustard (p < 0.01), but none from thiotepa nor cyclophosphamide.
In clinical practice there is some evidence that wounds made within a short
time of exposure to methotrexate do badly (Kiehn, Desprez and Benson, 1962;
Notaras, 1963, personal communication) with the incidence of wound infection
and disruption varying from 50-80 per cent.
There is general agreement, too, that the detrimental effect on healing of all
anti-cancer drugs is related to dosage. For this reason where high doses of an
anti-metabolite are used by infusion, the appropriate metabolite is given systemi-
cally. By such means a high concentration of methotrexate may be directed to
the required site while " leak " into the systemic circulation can be counter-
acted by folinic acid. This is standard clinical practice (Sullivan, Miller and
Sykes, 1959; Westbury, Humble, Pegg, Newton, Ford and White, 1962). Our
experimental results (experiment V) support the known protective action of
folinic acid, but naturally raise the question whether some folinic acid may also
neutralise the effect of methotrexate at the site of infusion. The use of folinic
acid may be an important factor in those tumours which show only partial
regression. Such thinking led Thomson and Foote (1963) to use intra-arterial
methotrexate without systemic folinic acid: the incidence of complications and
the therapeutic response in twenty-five patients differed little from those reported
by others.
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SUMMARY AND CONCLUSIONS
A study of the effect of methotrexate, in varying doses, on the tensile strength
of healing wounds has shown that:
1. In the dosage of 0 3 mg./kg./day tensile strength is depressed by 3000. The
comparable depression by 5-fluorouracil is 15 % and by cyclophosphamide nil.
2. Maximum depression occurs at a dose of 1P2 mg./kg. per day and a 50 %
reduction in wound strength is found at 0 5 mg./kg./day.
3. Depression of healing is more marked when the methotrexate is given after
wounding than before.
4. The protective effect offolinic acid is confirmed and there is a little evidence
that folinic acid enhances wound healing in the first few days.
5. The application of these results to clinical practice is discussed briefly.
For supplies of Methotrexate and Leucovorin we are grateful to Messrs.
Lederle Ltd.
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